Qt Group Plc, Stock Exchange Release October 31, 2016 at 3 pm The Finnish tax authorities have decided upon the determination for taxation purposes of the acquisition cost of shares of Digia Plc and Qt Group Plc, established through partial demerger from Digia Plc. According to the tax authorities' decision, Digia Plc and Qt Group Plc ratio of the fair value of the shares deviates by more than 30 percentage points in the ratio of net assets transferred to companies. Tax Administration considers such deviation significant. must be maintained. Therefore, fair values of the shares pursuant to 52 c § 5 of the Act on Taxation of Business Income shall be used as a division ratio in calculation of the acquisition cost of the shares. • based on the above, acquisition cost of Digia Plc's share shall be 48.14 per cent of Digia Plc's original acquisition cost before the partial demerger. • based on the above, acquisition cost of Qt Group Plc's share shall be 51.86 per cent of Digia Plc's original acquisition cost before the partial demerger. Further information (in Finnish) about the decision can be found at: http://www.vero.fi/fi -FI/Syventavat_veroohjeet/Verohallinnon_ohjeet/Digia_Oyjn_osittaisjakautumisessa _ syntyn(41081) Qt Group Plc Qt Group Plc is responsible for Qt development, productization and licensing under commercial and open source licenses. The Qt offering includes a development environment that enables the reuse of software code across numerous different operating systems, platforms and screen types, ranging from desktops and embedded systems to wearables and mobile devices. Qt is used by approximately 1 million developers worldwide and is the leading independent technology behind millions of devices and applications. Qt is the platform of choice for in-vehicle systems, industrial automation devices and other business critical applications manufacturers, and is used by leading global players in 70+ industries. The Qt Company operates in China, Finland, Germany, Japan, Korea, Norway, Russia and USA with about 200 employees worldwide. The Qt Group is headquartered in Espoo, Finland and is listed on Nasdaq Helsinki Stock Exchange. The company’s net sales in year 2015 was 27 MEUR. To learn more visit http://qt.io
Determination for taxation purposes of acquisition cost of
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Triumph Financial Sets Stage for Q4 Earnings and Insights
Triumph Financial Plans Fourth Quarter Earnings Release Triumph Financial, Inc. (Nasdaq: TFIN) recently announced its anticipation for the release of fourth quarter financial results. This event is scheduled to take place after the market closes on an upcoming Wednesday. Along with the financial report, the company will provide management commentary for stakeholders and...
Continue Reading
Monitoring ABA Therapy Progress: A Parent's Guide
The Nuts and Bolts of Progress Monitoring You've got a situation in Leominster where parents are trying to make sense of ABA therapy's impact on their kids. Rob Shapiro, a big name in the ABA world, breaks it all down in a HelloNation article. We're talking about precise data collection being the backbone of measuring progress in ABA therapy. This ain't no place for...
Continue Reading
Understanding Dowlais Group's Recent Market Activities
Public Disclosure Regarding Dowlais Group's Trading Activity FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code 1. KEY INFORMATION (a) Name of exempt principal trader: Investec Bank plc (b) Name of offeror/offeree in relation to whose r
Continue Reading
OFS Credit Company Reports Impressive Q4 Financials for 2024
OFS Credit Company Delivers Strong Q4 2024 Financial Results OFS Credit Company, Inc. (NASDAQ: OCCI), a notable investment firm focusing on collateralized loan obligation (CLO) equity and debt securities, has announced its financial performance for the fiscal quarter ending October 31, 2024. This report outlines the company’s significant financial growth and strategic...
Continue Reading
Breakthrough Data on HBI-8000 and Nivolumab for Melanoma
HBI-8000 and Nivolumab: A New Era in Melanoma Treatment Recent findings highlight the potential of HBI-8000 in combination with nivolumab, suggesting a transformative approach in the treatment of advanced melanoma. This promising combination will be discussed in detail at an upcoming prestigious annual meeting focused on advancements in immunotherapy. Innovative Solutions...
Continue Reading